Biomarker ID | 1094 |
PMID | 23574937 |
Year | 2013 |
Biomarker | miR-126 |
Biomarker Basis | Expression Based |
Biomolecule | miRNA |
Source | Plasma |
Subjects | Humans |
Regulation | Upregulated in metastatic castration-resistant PCa (mCRPC) |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include :- DNA-binding transcription factor activity, RNA polymerase II-specific; Gene expression (Transcription); RNA Polymerase II Transcription; Generic Transcription Pathway; nuclear chromatin |
Experiment | localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) |
Type of Biomarker | Prognostic |
Cohort | 25 PCa patients with treatment-naive localized disease (localized PCa) and 25 patients with metastatic castration resistant PCa and a rising PSA (mCRPC patients) were chosen for the study |
Senstivity | 48% |
Specificity | 96% |
AUC | 0.7488 [95% CI: 0.6100 - 0.8876] |
Accuracy | NA |
Level Of Significance | p < 0.001 |
Method Used | NA |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | miR-126 |